Biogen Inc. Common Stock (BIIB) — 分析摘要
Biogen Inc. Common Stock（BIIB）的市值为29.37十亿美元，最近一年的营收同比增长了+2.2%。净利润率为13.1%。当前市盈率为21.4倍。
核心要点
- 营收同比变化+2.2%
- 净利润率13.1%
- 市盈率21.4倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，BIIB的营收增长为+2.2%，市盈率为21.4倍。
Biogen Inc. Common Stock (BIIB)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 0.0x — 盈利不足以覆盖利息支出
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
7,500
总部
CAMBRIDGE, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。